文献速递预防保健、筛查与疫苗老年与多病共存

辉瑞与阿斯利康疫苗对英格兰老年人新冠症状、住院及死亡的有效性:检测阴性病例对照研究

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
PubMed 文献 · BMJ · 2021-05-13

单剂任一疫苗对症状性感染有效,并对重症有额外保护,两疫苗效果相似,且对B.1.1.7变异株有明确效果。

要点

  • 单剂BNT162b2或ChAdOx1-S对老年人症状性新冠有效,并额外降低住院和死亡风险。
  • 两疫苗效果相似,保护在研究随访期(>6周)内维持。
  • 疫苗对B.1.1.7变异株有明确效果。

核心结论

  • 接种一剂BNT162b2或ChAdOx1-S与老年人症状性新冠显著减少相关,并对重症有进一步保护。
  • 两疫苗效果相似,保护在随访期(>6周)内维持。
  • BNT162b2第二剂与症状性疾病进一步保护相关,且疫苗对B.1.1.7变异株有明确效果。

研究设计与样本

  • 检测阴性病例对照研究,设置于英格兰社区新冠检测。

主要发现

  • 80岁及以上在2021年1月4日前接种BNT162b2者,接种后首9天检测阳性比值比最高达1.48(95%CI 1.23至1.77),提示初始目标人群感染基线风险更高。
  • 与接种后基线期相比,接种后10至13天观察到疫苗效果,疫苗有效性达70%(95%CI 59%至78%),随后进入平台期;第二剂后14天起疫苗有效性为89%(95%CI 85%至93%)。
  • 70岁及以上自1月4日起接种者基线风险与未接种者相似:BNT162b2接种后28至34天疫苗有效性达61%(95%CI 51%至69%)后进入平台期;ChAdOx1-S接种后14至20天起效,28至34天有效性60%(95%CI 41%至73%),第35天起增至73%(95%CI 27%至90%)。
  • 在症状性疾病保护之外,接种一剂BNT162b2者急诊住院风险进一步降低43%(95%CI 33%至52%),死亡风险进一步降低51%(95%CI 37%至62%);接种一剂ChAdOx1-S者急诊住院风险进一步降低37%(95%CI 3%至59%)。
  • ChAdOx1-S对死亡率的影响因随访不足无法评估;结合对症状性疾病的效应,单剂任一疫苗预防新冠住院的有效性约80%,单剂BNT162b2预防新冠死亡的有效性为85%。

临床怎么用

  • 在老年人群中,单剂BNT162b2或ChAdOx1-S即可显著降低症状性新冠及重症风险,支持单剂接种的早期保护作用。
  • BNT162b2第二剂可进一步提高对症状性疾病的保护,完成全程接种对老年人具有额外获益。
  • 两疫苗对B.1.1.7变异株均有效,可为变异株流行期间的老年疫苗接种策略提供依据。

局限性

  • ChAdOx1-S对死亡率的影响因随访不足无法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. DESIGN: Test negative case-control study. SETTING: Community testing for covid-19 in England. PARTICIPANTS: 156 930 adults aged 70 years and older who reported symptoms of covid-19 between 8 December 2020 and 19 February 2021 and were successfully linked to vaccination data in the National Immunisation Management System. INTERVENTIONS: Vaccination with BNT162b2 or ChAdOx1-S. MAIN OUTCOME MEASURES: Primary outcomes were polymerase chain reaction confirmed symptomatic SARS-CoV-2 infections, admissions to hospital for covid-19, and deaths with covid-19. RESULTS: Participants aged 80 years and older vaccinated with BNT162b2 before 4 January 2021 had a higher odds of testing positive for covid-19 in the first nine days after vaccination (odds ratio up to 1.48, 95% confidence interval 1.23 to 1.77), indicating that those initially targeted had a higher underlying risk of infection. Vaccine effectiveness was therefore compared with the baseline post-vaccination period. Vaccine effects were noted 10 to 13 days after vaccination, reaching a vaccine effectiveness of 70% (95% confidence interval 59% to 78%), then plateauing. From 14 days after the second dose a vaccination effectiveness of 89% (85% to 93%) was found compared with the increased baseline risk. Participants aged 70 years and older vaccinated from 4 January (when ChAdOx1-S delivery commenced) had a similar underlying risk of covid-19 to unvaccinated individuals. With BNT162b2, vaccine effectiveness reached 61% (51% to 69%) from 28 to 34 days after vaccination, then plateaued. With ChAdOx1-S, effects were seen from 14 to 20 days after vaccination, reaching an effectiveness of 60% (41% to 73%) from 28 to 34 days, increasing to 73% (27% to 90%) from day 35 onwards. On top of the protection against symptomatic disease, a further 43% (33% to 52%) reduced risk of emergency hospital admission and 51% (37% to 62%) reduced risk of death was observed in those who had received one dose of BNT162b2. Participants who had received one dose of ChAdOx1-S had a further 37% (3% to 59%) reduced risk of emergency hospital admission. Follow-up was insufficient to assess the effect of ChAdOx1-S on mortality. Combined with the effect against symptomatic disease, a single dose of either vaccine was about 80% effective at preventing admission to hospital with covid-19 and a single dose of BNT162b2 was 85% effective at preventing death with covid-19. CONCLUSION: Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. Both vaccines showed similar effects. Protection was maintained for the duration of follow-up (>6 weeks). A second dose of BNT162b2 was associated with further protection against symptomatic disease. A clear effect of the vaccines against the B.1.1.7 variant was found.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021. PMID: 33985964. doi:10.1136/bmj.n1088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。